Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease

Brijen Shah, Lloyd Mayer

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

Crohns disease and ulcerative colitis are complex diseases that have required the use of multiple modalities to aid in treatment. With an increasing understanding of the underlying pathogenetic mechanisms and identification of specific therapeutic targets, monoclonal antibody treatment has been an ideal strategy for inducing and maintaining remission in these patients. This article addresses approved agents and the supporting data justifying their use in Crohns disease and ulcerative colitis, the safety of and immunologic reactions to these agents, as well as newer agents for treatment.

Original languageEnglish
Pages (from-to)607-620
Number of pages14
JournalExpert Review of Clinical Immunology
Volume6
Issue number4
DOIs
StatePublished - Jul 2010

Keywords

  • Crohns disease
  • infusion reaction
  • monoclonal antibody
  • tumor necrosis factor
  • ulcerative colitis

Fingerprint

Dive into the research topics of 'Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this